OBJECTIVES: To compare the outcomes of trans-subclavian (TS) and transapical (TA) access for transcatheter aortic valve implantation (TAVI). BACKGROUND: A considerable proportion of patients undergoing TAVI are not eligible for transfemoral approach. To date, there are few data to guide the choice between alternative vascular access routes. METHODS: Among 874 consecutive patients who underwent TAVI, 202 procedures were performed through TA (n = 142, 70.3%) or TS (n = 60, 29.7%) access. Medtronic Corevalve (CV, Medtronic, Minneapolis, MN) was implanted in 17.3% of the patients, the Edwards-Sapien (ES, Edwards Lifesciences Inc., Irvine, CA) in 81.2% and other prostheses in 0.1%. In-hospital and long-term outcome were assessed using the Valve Academic Research Consortium (VARC)-2 definitions. RESULTS: Mean age was 82 ± 6 years, STS score 9.3 ± 7.9%. The 2 groups showed a relevant imbalance in baseline characteristics. In hospital mortality was 6.4% (1.7% TS vs. 8.4% TA, P = 0.06), stroke 2.0%, acute myocardial infarction 1.0%, acute kidney injury 39.4%, sepsis 4.0% with no significant differences between groups, while bleeding was more frequent in TA patients (53.5% vs. 11.7% TS, P < 0.001). One- and 2-year survival was 85.2% and 73.2% in TS patients, and 83.9% and 74.9% in TA patients (P = ns for both). Access site was not an independent predictor of mortality at multivariable analysis. CONCLUSION: Transapical compared with trans-subclavian access for TAVI was associated with a nonsignificant trend to increased periprocedural events. However, 1- and 2-year survival appears similar.
OBJECTIVES: To compare the outcomes of trans-subclavian (TS) and transapical (TA) access for transcatheter aortic valve implantation (TAVI). BACKGROUND: A considerable proportion of patients undergoing TAVI are not eligible for transfemoral approach. To date, there are few data to guide the choice between alternative vascular access routes. METHODS: Among 874 consecutive patients who underwent TAVI, 202 procedures were performed through TA (n = 142, 70.3%) or TS (n = 60, 29.7%) access. Medtronic Corevalve (CV, Medtronic, Minneapolis, MN) was implanted in 17.3% of the patients, the Edwards-Sapien (ES, Edwards Lifesciences Inc., Irvine, CA) in 81.2% and other prostheses in 0.1%. In-hospital and long-term outcome were assessed using the Valve Academic Research Consortium (VARC)-2 definitions. RESULTS: Mean age was 82 ± 6 years, STS score 9.3 ± 7.9%. The 2 groups showed a relevant imbalance in baseline characteristics. In hospital mortality was 6.4% (1.7% TS vs. 8.4% TA, P = 0.06), stroke 2.0%, acute myocardial infarction 1.0%, acute kidney injury 39.4%, sepsis 4.0% with no significant differences between groups, while bleeding was more frequent in TA patients (53.5% vs. 11.7% TS, P < 0.001). One- and 2-year survival was 85.2% and 73.2% in TS patients, and 83.9% and 74.9% in TA patients (P = ns for both). Access site was not an independent predictor of mortality at multivariable analysis. CONCLUSION: Transapical compared with trans-subclavian access for TAVI was associated with a nonsignificant trend to increased periprocedural events. However, 1- and 2-year survival appears similar.
Authors: Adam B Greenbaum; Vasilis C Babaliaros; Marcus Y Chen; Annette M Stine; Toby Rogers; William W O'Neill; Gaetano Paone; Vinod H Thourani; Kamran I Muhammad; Robert A Leonardi; Stephen Ramee; James F Troendle; Robert J Lederman Journal: J Am Coll Cardiol Date: 2016-10-29 Impact factor: 24.094
Authors: Daniel Richard Watson; Steven Joseph Yakubov; Jefferson Morton Lyons; Carlos Enrique Sanchez Soto; Nathan Howard Kander; Anthony Theodore Chapekis; Arash Arshi; Aref Mahmoud Abou-Amro; Geoffrey B Blossom Journal: Ann Cardiothorac Surg Date: 2017-09
Authors: Jayendrakumar S Patel; Amar Krishnaswamy; Lars G Svensson; E Murat Tuzcu; Stephanie Mick; Samir R Kapadia Journal: Curr Cardiol Rep Date: 2016-11 Impact factor: 2.931
Authors: Thom G Dahle; Nathaniel J Castro; Brian M Stegman; Jacob R Dutcher; John M Teskey; Wade T Schmidt; Daren S Danielson; Sara J Dezell; Virginia B Daniels; Daniel J Tiede Journal: J Cardiothorac Surg Date: 2018-01-30 Impact factor: 1.637
Authors: Gerhard Schymik; Valentin Herzberger; Jens Bergmann; Peter Bramlage; Lars O Conzelmann; Alexander Würth; Armin Luik; Holger Schröfel; Panagiotis Tzamalis Journal: BMJ Open Date: 2018-10-25 Impact factor: 2.692